Description
-
Dose-Dependent Mass Acceleration
LGD-4033 (Ligandrol, VK5211) developed by Ligand Pharmaceuticals, represents the most potent clinically validated SARM for lean mass building—backed by completed Phase I and Phase II human trials demonstrating dose-dependent increases in lean body mass up to 9.1% in 12 weeks.
The Mechanism
LGD-4033 exhibits exceptional androgen receptor binding affinity, among the highest of any SARM developed. This sub-nanomolar binding creates potent agonistic activity in skeletal muscle and bone while maintaining partial agonist or antagonistic activity in the prostate and sebaceous glands. The compound demonstrates tissue selectivity independent of local drug concentration—meaning its preferential muscle activation is intrinsic to its molecular interaction with the androgen receptor, not simply pharmacokinetic distribution.
Anabolic Capacity
What separates LGD-4033 from other SARMs is its superior mass-building efficiency per milligram. Phase I clinical trials in 76 healthy young men demonstrated 2.67lb of lean body mass increase at just 1 mg daily for 21 days. Reports from users consistently document 5-10 lb lean mass gains within 4-8 week cycles at 5-10 mg daily, with strength increases of 50-100 lbs on compound movements when combined with structured training and caloric surplus.
LGD-4033 is pharmaceutical grade performance enhancement —
There are no reviews yet.